Innovent Biologics, Inc. · HKEX:1801

Innovent Biologics — H1 2019 Earnings Presentation

23 slides from Innovent Biologics's earnings presentation, August 2019

Slide 1: 2019 Interim Results Presentation
2019 Interim Results Presentation August 2019
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu
Slide 3: Our History
Our History 2011.8  Innovent was 2018 established  Listed on HKEX 2016  Filed NDA for IBI-303 (biosimilar  Strategic  IBI-301,IBI-303, IBI-305 2013 to adalimumab) with NMPA alliance with entered Phase III clinical  Tyvyt ® granted with marketing Adimab trials approval by the NMPA  Passed GMP
Slide 4: Major Accomplishments in 2019
Major Accomplishments in 2019 Clinical Pipeline Expansion Commercialization Corporate Milestone Advancement through Partnership 2 NDA SUBMITTED 1st LAUNCH AND STRATEGIC PARTNERSHIP EXPANSION OF NDA for IBI-305 (biosimilar to COMMERCIALIZATION WITH Eli Lilly and MANUFACTURING FACILITIES bevacizumab)
Slide 5: Robust Pipeline across Biologics and Small Molecules
Robust Pipeline across Biologics and Small Molecules Status (China) IND Candidate/ Target(s) Therapeutic Area: Disease Indications Commercial Rights Pre-clinical (Filed) (Accepted) Phase II Phase III NDA Launched Reference Drug Phase I Oncology: r/r Hodgkin’s lymphoma, 1L and 2L melanoma, refractory
Slide 6: Clinical Highlights of Sintilimab (Tyvyt®) and IBI-303 (Adalimumab Biosimilar)
Clinical Highlights of Sintilimab (Tyvyt®) and IBI-303 (Adalimumab Biosimilar) Cover Story of Sintilimab (Tyvyt®) Published at Inaugural Issue of by The Lancet Haematology The Lancet Rheumatology  Equivalence trial between IBI-303 and  Registration trial in 96 patients with relapsed adalimumab or
Slide 8: Commercialization of Sintilimab Injection - Tyvyt®
Commercialization of Sintilimab Injection - Tyvyt® March 9, 2019 SALES LAUNCHED Tyvyt® (sintilimab injection) 1H 2019 Sales reached RMB331.6 M Copyright© 2019 Innovent Biologics 7
Slide 9: Commercial Strategy
Commercial Strategy Stronger Brand to Generate Greater Demands BROADEN MARKET STRENGTHEN BUILD PENETRATION SHARE OF RECOGNITION & INCREASE VOICE & LEADERSHIP ACCESSIBILITY • Broaden coverage to • Further expand • Listed into CSCO 2019 lower-tier cities sales force treatment guideline • Expand DTP an
Slide 10: Build a Strong Competitive and Professional Sales Force with Scale by End of 2019
Build a Strong Competitive and Professional Sales Force with Scale by End of 2019 ~1,500 Target Hospital ~300 ~400 Cities DTP/Pharmacies Coverage 30 ~800 Provinces Coverage Commercial Team Size Copyright© 2019 Innovent Biologics 9
Slide 11: Clinical Development Programs for Sintilimab
Clinical Development Programs for Sintilimab Status Phase I Mono-/Combo-Therapy (Other NDA NDA Indication1, 2, 3 Components) Ia Ib Phase II Phase III Filed Approved China r/r Classical Hodgkin’s Lymphoma Mono 2L Classical Hodgkin’s Lymphoma Combo (ICE) 2L Squamous NSCLC Mono 1L Squamous NSCLC Combo
Slide 13: State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards
State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards M1b Facility: GMP commissioning and validation completed Total capacity in the future: 83KL 4 x 15,000 L Planned 5 x 1,000 L In Operation 6 x 3,000 L (cGMP validated) Ready in 2019 On 29 December
Slide 15: Global Partners
Global Partners August 22th, 2019 • Licensed in Lilly’s mid-stage potentially December 17th , 2018 global best-in-class diabetes product • Multi-product strategic collaboration candidate for China development and with Incyte commercialization • Licensed in 3 potentially best-in-class October 12th, 2
Slide 16: Deeper Collaboration with Lilly
Deeper Collaboration with Lilly OXM3 Licensed in a mid-stage potentially global best-in-class diabetes molecule product candidate for China development and commercialization Expanded efforts in metabolic diseases into the diabetes area 3 PD-1 bispecific mAbs Licensed out ex-China right of additional
Slide 17: Licensed-in Lilly’s Mid-stage Diabetes Molecule OXM3
Licensed-in Lilly’s Mid-stage Diabetes Molecule OXM3 Strengthen our metabolic portfolio with a first in China, potentially global best-in-class molecule RATIONALE that will be a strong entry point for Innovent to enter into diabetes, an attractive fast growing therapeutic area • OXM3 is an engineere
Slide 19: Organization Growth
Organization Growth 1,500 Organization Growth to Approximately 1,500 Employees1 CMC MANUFACTURING & QUALITY GENERAL AND ADMINISTRATIVE COMMERCIALIZATION TEAM R&D TEAM TEAM TEAM 450 530 400 120 1. As of June 30, 2019 Copyright© 2019 Innovent Biologics 18
Slide 20: Awards Industry-wide Recognition
Awards Industry-wide Recognition 2018 10th 2019 Gelonghui LACP 2018 Annual Anniversary Best Listed Vision Awards Achievement CHIC Companies - Gold Award Award IPO of the Year Award Copyright© 2019 Innovent Biologics 19
Slide 21: 2019 Outlook
2019 Outlook 1 2 SALES GROWTH PRODUCT LAUNCH PREPARATION Anticipate to continue the • Actively engage with the NMPA for the NDAs approval strong sales momentum for process for IBI-303, IBI-305 & the remainder of 2019 IBI-301 • Commercial preparation for products launch CLINICAL 2019 MANUFACTURING AD
Slide 22: 5-year Plan with Measurable Goals
5-year Plan with Measurable Goals 2025 2021 3 • >8 commercialized products • Multiple products entering late 2 2019 • 4 commercialized products • 5 products entering late stage clinical stage • Larger GMP manufacturing capacity • Tyvyt® launched sales development • 3 NDAs filed (IBI-303, IBI-305 & I

Innovent Biologics — H1 2019 Earnings Presentation on 6ix

Innovent Biologics — H1 2019 Earnings Presentation

Slide 1: 2019 Interim Results Presentation

Slide 2: Disclaimer

Slide 3: Our History

Slide 4: Major Accomplishments in 2019

Slide 5: Robust Pipeline across Biologics and Small Molecules

Slide 6: Clinical Highlights of Sintilimab (Tyvyt®) and IBI-303 (Adalimumab Biosimilar)

Slide 7: Agenda

Slide 8: Commercialization of Sintilimab Injection - Tyvyt®

Slide 9: Commercial Strategy

Slide 10: Build a Strong Competitive and Professional Sales Force with Scale by End of 2019

Slide 11: Clinical Development Programs for Sintilimab

Slide 12: Agenda

Slide 13: State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards

Slide 14: Agenda

Slide 15: Global Partners

Slide 16: Deeper Collaboration with Lilly

Slide 17: Licensed-in Lilly’s Mid-stage Diabetes Molecule OXM3

Slide 18: Agenda

Slide 19: Organization Growth

Slide 20: Awards Industry-wide Recognition

Slide 21: 2019 Outlook

Slide 22: 5-year Plan with Measurable Goals

Slide 23: Copyright© 2019 Innovent Biologics